Global Head, Business Development & Licensing Sandoz Small Molecules
Ben Toogood is Head Global BD&L and M&A at Sandoz International GmbH reporting directly to the CEO of Sandoz. He joined Sandoz from Aspen Pharmacare Holdings where he looked after pipeline and business development as the Group New Business Development Executive. Prior to that, Ben held various BD&L and Regulatory roles at a number of different companies, including Pharmathen, Niche Generics (Unichem Laboratories) and Merck Generics (Mylan). A British national, Ben holds a Pharmacy degree, Master Degree of Sciences in Medicine as well as an Executive MBA.